| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA948: Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments |
|
Medicine details |
|
| Medicine name | ivosidenib (Tibsovo®) |
| Formulation | oral |
| Reference number | 4316 |
| Indication | Treatment of cholangiocarcinoma (bile duct cancer) in patients with an isocitrate dehydrogenase 1 (IDH1) mutation, whose disease has progressed after one or two systemic therapies |
| Company | Servier Laboratories Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 24/03/2023 |
| NICE guidance | |